Compare · EW vs INGN
EW vs INGN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Inogen Inc (INGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and INGN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 304.0x INGN ($167.1M).
- EW has been more active in the news (5 items in the past 4 weeks vs 3 for INGN).
- EW has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Edwards Lifesciences Corporation
- Inogen Inc
- Price
- $86.61-1.66%
- $6.25-0.64%
- Market cap
- $50.78B
- $167.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest INGN
- Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
- Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
- SEC Form 4 filed by Inogen Inc
- EVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,500 shares, converted options into 18,136 shares and covered exercise/tax liability with 8,671 shares, increasing direct ownership by 50% to 32,972 units (SEC Form 4) (for tax liability)
- CEO and President Smith Kevin Raymond Merrill was granted 1,500 shares, increasing direct ownership by 1% to 134,962 units (SEC Form 4)
- SEC Form 10-Q filed by Inogen Inc
- Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inogen Announces Second Quarter 2026 Financial Results
- Smartbird Nominates Tech Industry Veterans Elizabeth Mora and Dan Kasun for Election to Its Board of Directors